Baseline screening tools as indicators for symptom outcomes and health services utilization in a collaborative care model for depression in primary care: a practice-based observational study

Shippee, Nathan D.; Rosen, Brooke H.; Angstman, Kurt B.; Fuentes, Manuel; DeJesus, Ramona S.; Bruce, Steven M.; Williams, Mark D.

doi:10.1016/j.genhosppsych.2014.06.014

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2014). Shippee et al . (2014) determined that 5 3% ( n = 80) of 1,507 depressed adults in PC drank hazardously (scored ≥8 on the AUDIT), and that hazardous drinking predicted a marginally lower likelihood of depression remission at 6-month follow-up.…”

Section: Resultsmentioning

confidence: 99%

Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review

Timko

Kong

Vittorio

et al. 2016

Journal of Clinical Nursing

View full text Add to dashboard Cite

Although small, the international evidence base suggests that screening with the Alcohol Use Disorders Identification Test or Alcohol Use Disorders Identification Test-C and brief interventions for primary care patients with chronic medical conditions, delivered by nurses or other providers, are effective for identifying unhealthy substance use and associated with healthy behaviours and improved outcomes. Lacking are studies screening for illicit drug use, and using single-item screening tools, which could be especially helpful for frontline primary care providers including nurses.

show abstract

Section: Resultsmentioning

confidence: 99%

Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review

Timko

Kong

Vittorio

et al. 2016

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

“…Previous studies of this pattern, which were limited to high-income Western countries (Kessler et al 2001; Jacobi et al 2004), found similar associations with those in the high-income WMH Surveys. The overrepresentation of anxious MDD in treatment populations is important because comorbid anxiety disorders predict both low MDD treatment persistence (Shippee et al 2014) and low MDD treatment response (Stiles-Shields et al 2014).…”

Section: Discussionmentioning

confidence: 99%

Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys

Kessler

Sampson²,

Berglund³

et al. 2015

Epidemiol Psychiatr Sci

456

242

View full text Add to dashboard Cite

AIMS To examine cross-national patterns and correlates of lifetime and 12-month comorbid DSM-IV anxiety disorders among people with lifetime and 12-month DSM-IV major depressive disorder (MDD). METHODS Nationally or regionally representative epidemiological interviews were administered to 74,045 adults in 27 surveys across 24 countries in the WHO World Mental Health (WMH) Surveys. DSM-IV MDD, a wide range of comorbid DSM-IV anxiety disorders, and a number of correlates were assessed with the WHO Composite International Diagnostic Interview (CIDI). RESULTS 45.7% of respondents with lifetime MDD (32.0–46.5% inter-quartile range [IQR] across surveys) had one of more lifetime anxiety disorders. A slightly higher proportion of respondents with 12-month MDD had lifetime anxiety disorders (51.7%, 37.8–54.0% IQR) and only slightly lower proportions of respondents with 12-month MDD had 12-month anxiety disorders (41.6%, 29.9–47.2% IQR). Two-thirds (68%) of respondents with lifetime comorbid anxiety disorders and MDD reported an earlier age-of-onset of their first anxiety disorder than their MDD, while 13.5% reported an earlier age-of-onset of MDD and the remaining 18.5% reported the same age-of-onset of both disorders. Women and previously married people had consistently elevated rates of lifetime and 12-month MDD as well as comorbid anxiety disorders. Consistently higher proportions of respondents with 12-month anxious than non-anxious MDD reported severe role impairment (64.4% vs. 46.0%; χ21=187.0, p<.001) and suicide ideation (19.5% vs. 8.9%; χ21=71.6, p<.001). Significantly more respondents with 12-month anxious than non-anxious MDD received treatment for their depression in the 12 months before interview, but this difference was more pronounced in high income countries (68.8% vs. 45.4%; χ21=108.8, p<.001) than low/middle income countries (30.3% vs. 20.6%; χ21=11.7, p<.001). CONCLUSIONS Patterns and correlates of comorbid DSM-IV anxiety disorders among people with DSM-IV MDD are similar across WMH countries. The narrow IQR of the proportion of respondents with temporally prior AOO of anxiety disorders than comorbid MDD (69.6–74.7%) is especially noteworthy. However, the fact that these proportions are not higher among respondents with 12-month than lifetime comorbidity means that temporal priority between lifetime anxiety disorders and MDD is not related to MDD persistence among people with anxious MDD. This, in turn, raises complex questions about the relative importance of temporally primary anxiety disorders as risk markers versus causal risk factors for subsequent MDD onset and persistence, including the possibility that anxiety disorders might primarily be risk markers for MDD onset and causal risk factors for MDD persistence.

show abstract

“…É inegável que a utilização de escalas de rastreamento nos sistemas de saúde, bem como na clínica, tem diversas vantagens e pode auxiliar na prevenção de recaídas, bem como direcionar os indivíduos a tratamentos mais eficazes (Shippee et al, 2014). Nesse sentido, a United States Preventive Services Task Force (USPSTF, 2017) vem recomendando a utilização de escalas de rastreamento em pacientes de serviços de saúde primários nos Estados Unidos desde 2009, no entanto, o rastreamento pode funcionar apenas como uma primeira etapa de uma avaliação mais aprofundada, no intuito da formulação do diagnóstico e/ou diagnóstico diferencial.…”

Section: As Diferentes Escalas De Avaliação De Depressãounclassified

Avaliando "depressões": dos critérios diagnósticos às escalas psicométricas

Baptista

2018

Aval.Psicol.

View full text Add to dashboard Cite

RESUMOO termo "depressão" pode ser utilizado para se referir a uma gama bastante abrangente de diagnósticos e expressões de sintomas, de maneira que duas pessoas podem apresentar sintomas completamente diferentes uma da outra e, mesmo assim, ambas terem diagnóstico semelhante. Nesse sentido, as escalas podem ser fundamentais no processo de rastreio, auxílio no diagnóstico e intervenção de pacientes com sintomatologia clinicamente significativa de depressão. Este artigo tem como objetivo discutir duas temáticas atuais que envolvem a avaliação psicológica. A primeira se refere a diferentes apontamentos (descrição, importância, críticas) sobre os critérios dos manuais psiquiátricos referentes aos transtornos depressivos. Na segunda temática, são discutidas características das escalas que avaliam sintomatologia depressiva e suas especificidades, já que elas podem ser distintas entre si, em vários aspectos, como teorias de base, dimensionalidade, número de itens, tipo de resposta, especificidades do ciclo de vida, formas de aplicação, dentre outros. Palavras-chave: transtornos de humor; transtornos afetivos; psicometria; escalas; avaliação psicológica.ABSTRACT -Evaluating "Depressions": from diagnostic criteria to psychometric scales The term "depression" can be used to refer to a fairly wide range of diagnoses and expressions of symptoms, so that two people may have completely different symptoms from each other, and yet both may have a similar diagnosis. Therefore, scales can be fundamental in the screening process, aiding in diagnosis and intervention with patients presenting clinically significant symptoms of depression. This article aims to discuss two current issues in psychological assessment. The first refers to different notes (description, importance, criticism) regarding the criteria in psychiatric manuals related to depressive disorders. The second theme discusses characteristics of the scales that evaluate depressive symptomatology and their specificities are discussed, since they may differ from each other, in several aspects such as basic theories, dimensionality, number of items, response type, life cycle specificities, application forms, among others. RESUMEN -Evaluación de las "depresiones": desde los criterios diagnósticos hasta las escalas psicométricasEl término "depresión" puede ser utilizado para referirse a una gama bastante amplia de diagnósticos y expresiones sintomáticas, de tal forma, que dos personas pueden presentar síntomas completamente diferentes una de la otra y, aun así, ambas pueden tener un diagnóstico similar. En este sentido, las escalas pueden ser fundamentales en el proceso de rastreo, ayuda en el diagnóstico e intervención en pacientes con sintomatología clínicamente significativa de depresión. Este artículo tiene como finalidad discutir dos temáticas de actualidad, que involucran a la evaluación psicológica. La primera se refiere a diferentes apuntes (descripción, importancia, críticas) sobre los criterios de los manuales psiquiátricos referentes a los trastornos depresivos. E...

show abstract

Baseline screening tools as indicators for symptom outcomes and health services utilization in a collaborative care model for depression in primary care: a practice-based observational study

Cited by 7 publications

References 30 publications

Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review

Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review

Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys

Avaliando "depressões": dos critérios diagnósticos às escalas psicométricas

Contact Info

Product

Resources

About